NO20080278L - Prodrugs av A2B-adenosinreseptorantagonister - Google Patents

Prodrugs av A2B-adenosinreseptorantagonister

Info

Publication number
NO20080278L
NO20080278L NO20080278A NO20080278A NO20080278L NO 20080278 L NO20080278 L NO 20080278L NO 20080278 A NO20080278 A NO 20080278A NO 20080278 A NO20080278 A NO 20080278A NO 20080278 L NO20080278 L NO 20080278L
Authority
NO
Norway
Prior art keywords
receptor antagonists
adenosine receptor
prodrugs
mammals
pro
Prior art date
Application number
NO20080278A
Other languages
English (en)
Norwegian (no)
Inventor
Dmitry Koltun
Jeff Zablocki
Rao Kalla
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20080278L publication Critical patent/NO20080278L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20080278A 2005-06-16 2008-01-15 Prodrugs av A2B-adenosinreseptorantagonister NO20080278L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69140805P 2005-06-16 2005-06-16
PCT/US2006/023167 WO2006138376A1 (fr) 2005-06-16 2006-06-14 Prodrogues d'antagonistes de recepteur d'adenosine a2b

Publications (1)

Publication Number Publication Date
NO20080278L true NO20080278L (no) 2008-02-28

Family

ID=37215988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080278A NO20080278L (no) 2005-06-16 2008-01-15 Prodrugs av A2B-adenosinreseptorantagonister

Country Status (14)

Country Link
US (3) US7625881B2 (fr)
EP (2) EP2301937A1 (fr)
JP (1) JP5044823B2 (fr)
KR (1) KR20080016645A (fr)
CN (1) CN101198608B (fr)
AU (1) AU2006259411B2 (fr)
CA (1) CA2612344A1 (fr)
IL (1) IL188103A0 (fr)
MX (1) MX2007015909A (fr)
NO (1) NO20080278L (fr)
NZ (1) NZ564326A (fr)
RU (2) RU2415858C2 (fr)
WO (1) WO2006138376A1 (fr)
ZA (1) ZA200710878B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
AU2004268964B2 (en) * 2003-08-25 2010-03-11 Allergan Sales, Llc Substituted 8-heteroaryl xanthines
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
WO2006091936A2 (fr) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Procedes permettant d'effectuer la synthese de xanthines a substitution cycloalkyle dissymetrique
EP2301937A1 (fr) 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrogues d'antagonistes de récepteurs A2b de l'adénosine
US7795268B2 (en) * 2006-03-17 2010-09-14 Gilead Palo Alto, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
WO2009088518A1 (fr) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. Antagonistes du récepteur d'adénosine a2b pour le traitement du cancer
WO2009157938A1 (fr) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. Antagonistes de récepteur d’adénosine a2b pour traiter le cancer
AU2010339691B2 (en) 2010-01-07 2015-04-02 Alkermes Pharma Ireland Limited Prodrugs of heteraromatic compounds
CN103237548A (zh) * 2010-06-30 2013-08-07 吉利德科学股份有限公司 A2b腺苷受体拮抗剂用于治疗肺高血压的应用
EP2616470B1 (fr) 2010-09-13 2016-10-12 Advinus Therapeutics Limited Composés purine utilisés en tant que promédicaments des antagonistes du récepteur a2b de l'adénosine, leur procédé de préparation et leurs applications médicales
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
JP2014514300A (ja) * 2011-04-08 2014-06-19 スファエラ ファーマ ピーティーイー リミテッド 置換メチルホルミル試薬並びに化合物の物理化学的性質及び／又は薬物動態学的性質を改質するためのそれらの使用方法
ES2656087T3 (es) 2012-06-08 2018-02-23 Gilead Sciences, Inc. Inhibidores macrocíclicos de virus Flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
JP6209601B2 (ja) 2012-06-08 2017-10-04 ギリアード サイエンシーズ， インコーポレイテッド フラビウイルス科ウイルスの大環状阻害剤
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
US10308671B2 (en) * 2015-12-14 2019-06-04 Max-Planck-Gesellschaft Zur Forderung Water-soluble derivatives of 3,5-diphenyl-diazole compounds
CA3093234A1 (fr) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Antagonistes du recepteur de l'adenosine et leurs utilisations
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6815446B1 (en) * 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
EP1255550A2 (fr) * 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Procede d'identification et d'utilisation d'antagonistes du recepteur d'adenosine a2b pour agir sur la proliferation cellulaire d'un mammifere
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
CN100467469C (zh) * 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) * 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2003053366A2 (fr) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Composes pyrimidine antagonistes selectifs des recepteurs a2b, leur synthese et leur utilisation
EP1601649A4 (fr) * 2003-02-19 2009-03-04 Endacea Inc Antagonistes du recepteur de l'adenosine a1
DK1622908T3 (da) * 2003-05-06 2008-11-17 Cv Therapeutics Inc Xanthin-derivater som A2B adenosin-receptor-antagonister
AU2004268964B2 (en) * 2003-08-25 2010-03-11 Allergan Sales, Llc Substituted 8-heteroaryl xanthines
MXPA06004789A (es) * 2003-10-31 2006-07-03 Cv Therapeutics Inc Antagonistas del receptor de adenosina a2b.
SI1789053T1 (sl) * 2004-09-01 2012-09-28 Gilead Sciences Inc Postopek celjenja rane z uporabo antagonistov A2B adenozinskih receptorjev
NZ589657A (en) * 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
EP2301937A1 (fr) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrogues d'antagonistes de récepteurs A2b de l'adénosine
US7795268B2 (en) * 2006-03-17 2010-09-14 Gilead Palo Alto, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists
ES2437871T3 (es) * 2006-07-07 2014-01-14 Gilead Sciences, Inc. Moduladores del receptor tipo toll 7
CN102015712A (zh) * 2008-03-26 2011-04-13 阿德维纳斯治疗私人有限公司 作为腺苷受体拮抗剂的杂环化合物

Also Published As

Publication number Publication date
US20100056538A1 (en) 2010-03-04
CA2612344A1 (fr) 2006-12-28
JP5044823B2 (ja) 2012-10-10
WO2006138376A1 (fr) 2006-12-28
ZA200710878B (en) 2009-05-27
AU2006259411A1 (en) 2006-12-28
US20110160162A1 (en) 2011-06-30
US7625881B2 (en) 2009-12-01
EP1891070A1 (fr) 2008-02-27
MX2007015909A (es) 2008-03-06
US8143249B2 (en) 2012-03-27
CN101198608A (zh) 2008-06-11
NZ564326A (en) 2010-01-29
IL188103A0 (en) 2008-03-20
RU2415858C2 (ru) 2011-04-10
JP2008543860A (ja) 2008-12-04
CN101198608B (zh) 2011-04-27
RU2007146669A (ru) 2009-06-20
US20060293283A1 (en) 2006-12-28
AU2006259411B2 (en) 2012-03-22
KR20080016645A (ko) 2008-02-21
EP2301937A1 (fr) 2011-03-30
RU2010150615A (ru) 2012-06-20

Similar Documents

Publication Publication Date Title
NO20080278L (no) Prodrugs av A2B-adenosinreseptorantagonister
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DE602005020127D1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
ATE496924T1 (de) Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
PL2041093T3 (pl) Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
DK1765844T3 (da) Purin-nukleotidderivater
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
BRPI0511124A (pt) pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
ATE556080T1 (de) Purinderivat
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI0910789A2 (pt) substratos tendo formulações com capacidade de transferência aperfeiçoada
DE602005027225D1 (de) Autonomes system mit beweglichem körper
NO20081923L (no) Adenosin A2a-reseptorantagonister for behandling av ekstra-pyramidalt syndrom og andre bevegelsesforstyrrelser
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
ZA200803236B (en) Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders
ITTO20050022A1 (it) Impianto di alimentazione del carburante
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
DK2059521T3 (da) Pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelse og sammensætninger
DE602004015344D1 (de) Quellenspezifisches multicast-routing
ITMI20052231A1 (it) Struttura perfezionata di espansore rapido del palato
FR2866223B1 (fr) Article de literie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application